Brought to you by 
BTG gets US rights to Wellstat’s 5-FU antidote
11 Dec 2015
Executive Summary
BTG International Inc., the US division of BTG PLC has licensed exclusive rights to market Wellstat Therapeutics Corp.’s (neurology, metabolic, and oncology) investigational drug uridine triacetate (PN401) in the US for up to ten years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BTG gets US rights to Wellstat’s 5-FU antidote
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice